Epidermal growth factor receptor (EGFR) is frequently overexpressed in the majority of triple negative breast cancer patients (TNBC). However, the molecular determinants behind their limited response to EGFR-targeted therapies are poorly understood. Here, both the acute and chronic responses of TNBC to the EGFR-targeted therapy, cetuximab (CTX), have been investigated. The expression of EGFR has been analyzed in a cohort of 2000 breast cancer tumours from the public dataset as well as in a panel of breast cancer cell lines. Furthermore, the response of TNBC cell lines to CTX has been investigated using conventional biochemical methods. Finally, a comprehensive transcriptomic profiling of an acquired CTX-resistant TNBC model by RNA sequencing has been performed to understand the molecular determinants of acquired CTX resistance. The results confirmed that EGFR is highly expressed in TNBC in comparison to non-TNBC breast cancer tumours and cell lines, which was associated with adverse clinical outcomes. Targeting EGFR in TNBC cell lines using CTX failed to completely inhibit the EGFR signalling pathway and was associated with an increase in ADAMs-mediated release of endogenous EGFR ligands, EGF and TGFα. Inhibition of ADAMs (ADAM10 and ADAM17) significantly enhanced the anti tumour efficacy of CTX both in vitro and in vivo. Furthermore, transcriptomic profiling of the acquired CTX-resistant TNBC cell line (MDA-MB-468CR) revealed an activation of several key oncogenic pathways and genes, including the TGFβ/BMP pathway. Blocking BMP receptors (BMPRs) restored the sensitivity of resistant cells to CTX treatment. Collectively, current findings offer alternative strategies that could enhance the CTX response in TNBC. We further reported that simultaneous targeting of both EGFR and BMPR pathways could overcome CTX resistance, which might have important implications for the treatment of TNBC.

Em mulheres, o câncer de mama é o tipo mais incidente depois do tumor de pele não melanoma e é a principal causa de morte por câncer. Apesar dos avanços já alcançados na caracterização da doença, a busca por novos marcadores moleculares para diagnóstico, tratamento e entendimento molecular da doença é de extrema importância. Estudos em nosso laboratório apontaram a proteína EMC1 (do inglês, Endoplasmic Reticulum Complex 1) como relacionada a propriedades malignas em linhagens celulares de câncer de mama e melanoma, assim como aumento no crescimento tumoral em ensaios in vivo. Despertou-se, então, o interesse em nosso laboratório, no estudo das outras proteínas do complexo EMC. Este estudo atual, busca analisar dados em larga escala do banco TCGA em um painel de 32 tipos tumorais, e aponta associação da expressão de diversas proteínas EMCs a pior sobrevida dos pacientes. O gene EMC2, que se localiza na região cromossômica altamente amplificada em diversos tumores (8q23.1), se destaca pela intensidade de pacientes com superexpressão em câncer de mama (40%). Em linhagens desse tipo tumoral, o knockdown de EMC2 aponta redução na taxa proliferativa, assim como associação à progressão do ciclo celular na fase M, quando feito o protocolo de sincronização utilizando a droga nocodazol. Em conjunto, nossos dados sugerem que o complexo EMC pode favorecer o desenvolvimento de tumores e influenciar em sua malignidade. Além disso, a proteína EMC2 parece apresentar funções relacionadas a proliferação e possivelmente, ciclo celular. / In woman, the breast cancer is the most incidence type after skin tumor non melanoma and it is a main cause of cancer death. Despite the advances already achieved in the disease caracterization, the search for novel molecular biomarkers to diagnostic, treatment and disease knowledge is extremely importante. In vitro approaches pointed Endoplasmic Reticulum Complex 1 (EMC1) involvement in malignant properties in breast cancer and melanoma cell lines, and increase in tumor growth in a in vivo assay. It highlighted the study of the other members of EMC complex. In this study, we used a large-scale database from TCGA in a range of 32 tumoral types, and showed association in EMC expression and poor surviving curve. The EMC2 gene, localized in a high amplified chromosome region in cancer (8q23.1), have a interesting upregulation level in breast cancer (40%). In knockdown EMC2 cell lines, the proliferation is less intense and progression in M phase, in a nocodazole sincronization assay, is impaired. Together, the data suggest that the EMC complex favors the tumour development and the EMC2 protein seens to play a role in proliferation and maybe in cell cycle.

O ácido linoleico conjugado (CLA), um grupo de isômeros do ácido linoleico, é encontrado no leite e na carne de animais ruminantes, e apresenta propriedades anticarcinogênica, antidiabética, antiadipogênica e antiaterogênica. Neste trabalho de doutorado estudou-se o efeito do CLA (cis-9, trans-11) em duas linhagens de células de câncer de mama, MCF-7 e MDA-MB-231, com a técnica de RMN denominada HR-MAS (High Resolution Magic Angle Spinning). O HR-MAS foi usado para identificar e quantificar os principais metabólitos das linhagens e também foi eficiente para observar mudanças significativas na variação dos metabólitos em função da adição de CLA ao meio de cultura. As células de câncer de mama, MCF-7 submetidas a 100 µM CLA tiveram aumento significativo do sinal de acetona. Esse padrão não foi observado para a MDA-MB-231. Também se observou que o teor de fosfocolina decresceu em ambas as linhagens celulares quando tratadas com 100 µM CLA. Mediante esses resultados e simulação por modelagem molecular propôs-se que o CLA pode atuar inibindo a ação da enzima HMG-CoA redutase (HMGR), de maneira similar as estatinas. Ao se ligar a HMGR, o CLA impede a ligação do HMG-CoA (substrato), impedindo a sua conversão para mevalonato e consequentemente a biossíntese do colesterol. O HMG-CoA é então convertido para acetoacetato e posteriormente a acetona. Esse mecanismo pode explicar tanto o aumento da acetona quanto a redução da fosfocolina, uma vez que há controle positivo mútuo entre o colesterol e os fosfolipídios. Desta forma, pode-se concluir que a inibição da HMGR pelo CLA pode ser uma demonstração do mecanismo bioquímico tanto de sua ação anticarcinogênica quando das atividades antidiabética, antiadipogênica e antiaterogênica, relatadas na literatura. Neste trabalho também foi demonstrada a potencialidade do processamento dos sinais de HR-MAS no domínio do tempo pelo método de diagonalização filtrada. Essa técnica foi capaz de obter espectros de alta resolução, sem necessidade de supressão do sinal da água e filtro de T2, para suprimir linhas largas. / Conjugated linoleic acid (CLA), a group of isomers of linoleic acid,is found in milk and meat of ruminant animals, which have anticarcinogenic, antidiabetic, antiatherogenic and anthiadipogenic properties. In this thesis the effect of CLA (cis-9, trans-11) in two cell lines of breast cancer, MCF-7 and MDA-MB-231 was studied High Resolution Magic Angle Spinning (HR-MAS) NMR technique. HR-MAS was used to identify and quantify the metabolites of the two cells and was effective to observe significant changes in metabolites due to the addition of CLA to the culture medium. The breast cancer cells, MCF-7 subjected to 100 µM CLA had a significantly higher acetone signal. This pattern was not observed for MDA-MB-231. It was noted that the content of phosphocholine decreased in both cell lines treated with 100 µM CLA. Given these results and simulation with molecular modeling we are suggesting that CLA inhibits the enzyme HMG-CoA reductase (HMGR), similar to statins. By binding to HMGR, CLA prevents binding of the HMG-CoA (substrate), preventing their conversion to mevalonate, and consequently the cholesterol biosynthesis. The HMG-CoA is then converted to acetoacetate and then acetone. This mechanism explains the increase of acetone and decreased of phosphocholine, since there is mutual positive control with cholesterol and phospholipids. Therefore, the inhibition of HMGR by CLA may be the biochemical explanation for its anticarcinogenic activities as well as antidiabetic, antiatherogenic and antiadipogenic properties reported in the literature. It was also demonstrated the capability of Filter Diagonalization Method (FDM) to process time domain HR-MAS signals. FDM was able to obtain high-resolution spectra without the water suppression and T2 filter.

O ácido linoleico conjugado (CLA), um grupo de isômeros do ácido linoleico, é encontrado no leite e na carne de animais ruminantes, e apresenta propriedades anticarcinogênica, antidiabética, antiadipogênica e antiaterogênica. Neste trabalho de doutorado estudou-se o efeito do CLA (cis-9, trans-11) em duas linhagens de células de câncer de mama, MCF-7 e MDA-MB-231, com a técnica de RMN denominada HR-MAS (High Resolution Magic Angle Spinning). O HR-MAS foi usado para identificar e quantificar os principais metabólitos das linhagens e também foi eficiente para observar mudanças significativas na variação dos metabólitos em função da adição de CLA ao meio de cultura. As células de câncer de mama, MCF-7 submetidas a 100 µM CLA tiveram aumento significativo do sinal de acetona. Esse padrão não foi observado para a MDA-MB-231. Também se observou que o teor de fosfocolina decresceu em ambas as linhagens celulares quando tratadas com 100 µM CLA. Mediante esses resultados e simulação por modelagem molecular propôs-se que o CLA pode atuar inibindo a ação da enzima HMG-CoA redutase (HMGR), de maneira similar as estatinas. Ao se ligar a HMGR, o CLA impede a ligação do HMG-CoA (substrato), impedindo a sua conversão para mevalonato e consequentemente a biossíntese do colesterol. O HMG-CoA é então convertido para acetoacetato e posteriormente a acetona. Esse mecanismo pode explicar tanto o aumento da acetona quanto a redução da fosfocolina, uma vez que há controle positivo mútuo entre o colesterol e os fosfolipídios. Desta forma, pode-se concluir que a inibição da HMGR pelo CLA pode ser uma demonstração do mecanismo bioquímico tanto de sua ação anticarcinogênica quando das atividades antidiabética, antiadipogênica e antiaterogênica, relatadas na literatura. Neste trabalho também foi demonstrada a potencialidade do processamento dos sinais de HR-MAS no domínio do tempo pelo método de diagonalização filtrada. Essa técnica foi capaz de obter espectros de alta resolução, sem necessidade de supressão do sinal da água e filtro de T2, para suprimir linhas largas. / Conjugated linoleic acid (CLA), a group of isomers of linoleic acid,is found in milk and meat of ruminant animals, which have anticarcinogenic, antidiabetic, antiatherogenic and anthiadipogenic properties. In this thesis the effect of CLA (cis-9, trans-11) in two cell lines of breast cancer, MCF-7 and MDA-MB-231 was studied High Resolution Magic Angle Spinning (HR-MAS) NMR technique. HR-MAS was used to identify and quantify the metabolites of the two cells and was effective to observe significant changes in metabolites due to the addition of CLA to the culture medium. The breast cancer cells, MCF-7 subjected to 100 µM CLA had a significantly higher acetone signal. This pattern was not observed for MDA-MB-231. It was noted that the content of phosphocholine decreased in both cell lines treated with 100 µM CLA. Given these results and simulation with molecular modeling we are suggesting that CLA inhibits the enzyme HMG-CoA reductase (HMGR), similar to statins. By binding to HMGR, CLA prevents binding of the HMG-CoA (substrate), preventing their conversion to mevalonate, and consequently the cholesterol biosynthesis. The HMG-CoA is then converted to acetoacetate and then acetone. This mechanism explains the increase of acetone and decreased of phosphocholine, since there is mutual positive control with cholesterol and phospholipids. Therefore, the inhibition of HMGR by CLA may be the biochemical explanation for its anticarcinogenic activities as well as antidiabetic, antiatherogenic and antiadipogenic properties reported in the literature. It was also demonstrated the capability of Filter Diagonalization Method (FDM) to process time domain HR-MAS signals. FDM was able to obtain high-resolution spectra without the water suppression and T2 filter.

Orientador: Christiane Pienna Soares / Banca: Christiane Pienna Soares / Banca: Haroldo Wilson Moreira / Banca: Ana Marisa Fusco Almedia / Banca: Raquel Alves dos Santos / Banca: Maria Regina Torqueti Toloi / Resumo: O câncer de mama é a maior causa de morbidade e mortalidade entre as mulheres no mundo. Pesquisas revelam vários fatores prognósticos e preditivos para a identificação de pacientes com alto risco de agressividade, metastases e doença recorrente na condição de combater estas estatísticas. Por esta razão, é evidente a necessidade do desenvolvimento de estratégias de tratamento mais eficazes. Estudos prévios com Pterogyne nitens Tul. (Fabaceae-Caesalpinioideae), uma planta nativa do Brasil resultou o isolamento de dois alcalóides guanidínicos. Exibiram atividade seletiva direcionada a DNA deficiente de reparo, sugerindo potencial atividade anticâncer. Objetivo: O objetivo do presente estudo foi avaliar a citotoxicidade e apoptose induzidas pelos alcalóides pteroginina (PGN) and pteroginidina (PGD) em linhagem de adenocarcinoma (MCF-7) e carcinoma ductal invasivo (ZR-7531). Materiais e Métodos: As duas linhagens celulares foram tratadas pelos alcalóides em várias concentrações (0.25 - 10 mM) em dois tempos, t0 (24h) e t24 (24h seguido por 24h pós-tratamento). O ensaio de citotoxicidade foi determinado pelo teste de MTT; a morte celular (apoptose e necrose) foi analisada usando os métodos Hoechst 33342/iodeto propídio, Kit de Anexina V-FITC e atividade de Caspases 3/7. Resultados: Os tratamentos com os alcalóides demonstraram citotoxicidade concentração-resposta nas linhagens de câncer de mama. Para avaliação da apoptose foi observado um intense efeito concentraçãoresposta em apoptose tardia/necrose e discreto sinal para apoptose precoce em todas concentrações (p<0,01). No ensaio Hoechst/iodeto, observou diferença significante entre os estágios de apoptose precoce e tardia de ambas linhagens. A pteroginina no período t0 e t24, e pteroginidina no período t0 demonstraram possuir intenso efeito concentração... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Breast cancer is a major cause of morbidity and mortality among women worldwide. Research has elucidated several specific prognostic and predictive factors to identify patients at high risk of the aggressive disease, metastasis and recurrence of the disease in order to combat these statistics. For this reason, there is an obvious need to develop more efficacious treatment strategies. Previous studies on Pterogyne nitens Tul. (Fabaceae-Caesalpinioideae), a native plant of Brazil, resulted in the isolation of two guanidine alkaloids, exhibited selective activity towards a DNA repair-deficient, suggesting potential anti-cancer activity. Objective: The aim of the present study was to evaluate the citotoxicity and apoptosis induced by alkaloids pterogynine (PGN) and pterogynidine (PGD) in human adenocarcinoma cell line (MCF-7) and human invasive ductal carcinoma cell line(ZR-7531). Material and Methods: The two cell lines were treated by both alkaloids at several concentrations (0.25 - 10 mM) and two time points, 24h (t0) and 24h followed by 24h pos-treatment (t24). The cytotoxicity assay was determined by MTT assay; the cell death (apoptosis and necrosis) were analyzed using the dye Hoechst 33342/propidium iodide, Annexin V-FITC and Caspase 3/7 activity. Results: The treatments with the alkaloids demonstrated citotoxicity effect concentrationresponse in breast cell lines. Apoptosis evaluation, pterogynine and pterogynidine has an intense effect concentration-response of late apoptosis/necrosis and a discrete signal of early apoptosis in all of the concentrations (p<0.01). Hoechst/iodide assay, it was observe significant difference among the stages of early and late apoptosis in the both cells lines. Pterogynine for the period of t0 and t24, and pterogynidine for the period of t0 demonstrated to possess an intense concentrationresponse... (Complete abstract click electronic access below) / Doutor

Em mulheres, o câncer de mama é o tipo mais incidente depois do tumor de pele não melanoma e é a principal causa de morte por câncer. Apesar dos avanços já alcançados na caracterização da doença, a busca por novos marcadores moleculares para diagnóstico, tratamento e entendimento molecular da doença é de extrema importância. Estudos em nosso laboratório apontaram a proteína EMC1 (do inglês, Endoplasmic Reticulum Complex 1) como relacionada a propriedades malignas em linhagens celulares de câncer de mama e melanoma, assim como aumento no crescimento tumoral em ensaios in vivo. Despertou-se, então, o interesse em nosso laboratório, no estudo das outras proteínas do complexo EMC. Este estudo atual, busca analisar dados em larga escala do banco TCGA em um painel de 32 tipos tumorais, e aponta associação da expressão de diversas proteínas EMCs a pior sobrevida dos pacientes. O gene EMC2, que se localiza na região cromossômica altamente amplificada em diversos tumores (8q23.1), se destaca pela intensidade de pacientes com superexpressão em câncer de mama (40%). Em linhagens desse tipo tumoral, o knockdown de EMC2 aponta redução na taxa proliferativa, assim como associação à progressão do ciclo celular na fase M, quando feito o protocolo de sincronização utilizando a droga nocodazol. Em conjunto, nossos dados sugerem que o complexo EMC pode favorecer o desenvolvimento de tumores e influenciar em sua malignidade. Além disso, a proteína EMC2 parece apresentar funções relacionadas a proliferação e possivelmente, ciclo celular. / In woman, the breast cancer is the most incidence type after skin tumor non melanoma and it is a main cause of cancer death. Despite the advances already achieved in the disease caracterization, the search for novel molecular biomarkers to diagnostic, treatment and disease knowledge is extremely importante. In vitro approaches pointed Endoplasmic Reticulum Complex 1 (EMC1) involvement in malignant properties in breast cancer and melanoma cell lines, and increase in tumor growth in a in vivo assay. It highlighted the study of the other members of EMC complex. In this study, we used a large-scale database from TCGA in a range of 32 tumoral types, and showed association in EMC expression and poor surviving curve. The EMC2 gene, localized in a high amplified chromosome region in cancer (8q23.1), have a interesting upregulation level in breast cancer (40%). In knockdown EMC2 cell lines, the proliferation is less intense and progression in M phase, in a nocodazole sincronization assay, is impaired. Together, the data suggest that the EMC complex favors the tumour development and the EMC2 protein seens to play a role in proliferation and maybe in cell cycle.

No description available.

Cytochrome P450 enzymes (P450s) are involved in cancer development and treatment due to their roles in the oxidative metabolism of various endogenous (e.g. oestrogen) and exogenous (e.g. tamoxifen) compounds. It is well-known that intermediate P450 metabolites derived from oestrogen metabolism are associated with breast carcinogenesis. The main aim of this project was to profile the cytochrome P450 and P450-regulatory nuclear receptor mRNAs in a series of breast cancer cell lines (BCCs) and compare this profile with normal breast cells. This study used the qualitative reverse transcriptasepolymerase chain reaction (RT-PCR) to detect mRNA expression of target genes. Results showed CYP1B1, CYP2D6, CYP2J2, CYP2R1, CYP2U1 and CYP4X1 mRNA to be present in all cell lines. CYP2A6, CYP2C8, CYP2C18, CYP2F1 and CYP4Z1 mRNA were expressed in oestrogen receptor (ER)-positiveCaucasian and ER-negative Afro- Caribbean BCCs. Although no differences in P450 mRNA were observed between the different ethnic groups, these preliminary findings suggest potential similarities in the ERpositive Caucasian and ER-negative Afro-Caribbean BCCs which warrant further investigation The CYP4Z1 PCR product was identified as two distinct bands. Specific primer sets were used to demonstrate potential intron retention in CYP4Z1. Using established in vitro models for the study of regulatory mechanisms of CYP4Z1, T47D and ZR-75-1 breast cancer cell lines were used to determine the appropriate nuclear receptors (i.e. progesterone receptor, glucocorticoid receptor or peroxisome proliferator-activated receptor alpha ). These findings suggest that there may be an alternative receptor mechanism involved in CYP4Z1 mRNA induction in these cells. In conjunction, pre-treatment of these two cell lines with the RNA synthesis inhibitor actinomycin D followed by the agonists showed a significant reduction (p < 0.05) of CYP4Z1 mRNA levels and inhibited CYP4Z1 induction by either progesterone, dexamethasone or pirinixic acid, indicating that these agonists have effects on CYP4Z1 mRNA transcription or stability. In contrast, cycloheximide differentially affected the level of CYP4Z1 mRNA induction by these agonists. Taken together, these results suggest that CYP4Z1 mRNA induction in T47D and ZR-75-1 is mediated through differential cell type specific regulatory mechanisms and there is evidence for differential regulation of the splice variants.

L'objectif de cette thèse est d'étudier la sensibilité des lignes cellulaires du cancer du sein BTCL aux agents stabilisants des microtubules (taxanes et ixabépilone) afin de: 1 - identifier la pharmaco-génomique prédictif de la réponse (résistance / sensibilité) comme une signature moleculaire, et de valider cette signature sur d'autres études dont les données génomiques sont disponibles en ligne, donc mis l'expression des gènes prédictifs de GES pour Tax- sensibilité (333 gènes ) et Ixa-sensibilité (79 gènes) ont été définis, et les Taxanes prédicateurs GES a considérablement prédit Pac-sensibilité dans BTCL, et pathologiques réponse complète à base de Pac-chimiothérapie néoadjuvante chez les patients du cancer du sein. 2 - étudier le rôle des cellules souches du cancer (ALDH +) sur la réponse thérapeutique aux Taxanes et donc, Nous identifions quatre lignes BTCL qui présentent un enrichissement significative dans le pourcentage et le nombre absolu de ALDELFUOR cellules positives dans chacun de ces quatre BTCLs après 5 jours de traitement par le paclitaxel, en contraste avec les résultats précédents, nous avons constaté que dans ces autres 3 BTCLs le phénomène est inversé avec la diminution significative du pourcentage et le nombre absolu de cellules positives ALDELFUOR trouve dans chacun de ces trois BTCLs après 5 jours du traitement par le paclitaxel. Une signature moléculaire de SCC résistant / sensible de 243 pb avec 179 gènes dont 152 gènes sont régulés à la hausse et 27 gènes régulés à la baisse au CSC résistantes au paclitaxel, une sorte prédicteurs génomiques pour Tax - sensibilité au CSC résistantes au paclitaxel peut être dérivée à partir BTCL et peut être utile pour mieux comprendre les mécanismes de résistance aux taxanes et de l'implication de la CSC dans cette résistance, afin de mieux sélectionner des traitements cytotoxiques chez les patients du cancer du sein et l'identification des d'autres marqueurs potentiels de thérapies ciblées dans l'avenir. 3 - Nous avons testé l'impact de l'altération des paramètres génomiques et protéiques ou les mutations de certains gènes comme tau (MAPT), K-alpha tubuline (TUB A1B) tubuline alpha-6 (A1C TUB) tubuline beta 3 (TUBB3) et stathmine (STMN1), malheureusement nous n'avions jamais identifier une mutation pour être corrélée à la réponse des BTCL aux Taxanes. 4 - Nous essayons d'étudier au niveau de protéines par immunohistochimie sur le tissu de micro-array et cyto-micro-array pour certains paramètres qui ont été déjà prouvé (in vitro) pour être corrélée à la réponse aux Taxanes, (cette partie est en fait en cours). / The aim of this thesis is to study the sensitivity of breast cancer cell lines BTCL to microtubule-stabilizing agents (Taxanes and ixabepilone) in order to:1- identify pharmaco-genomic predictor of response (resistance /sensitivity) as a molecular signature, and to validate this signature on others studies of which the genomic data are available on line, so gene expression set GES predictors for Tax-sensitivity (333 genes) and Ixa-sensitivity (79 genes) were defined, and the Taxanes GES predictors has significantly predicted Pac-sensitivity in BTCL, and pathological complete response to Pac-based neo-adjuvant chemotherapy in BC patients.2- study the role of cancer stem cell (ALDH+) on the therapeutic response to Taxanes and their we identify 4 BTCLs which present a significant enrichment in the percentage and the absolute numbers of ALDELFUOR-positive cells found in each of these 4 BTCLs after 5 days of treatment by Paclitaxel , In contrast to the previous results we found that in others 3 BTCLs these phenomenon is inversed with the significant decrease of the percentage, and the absolute numbers of ALDELFUOR-positive cells found in each of these 3 BTCLs after 5 days of treatment by Paclitaxel.A molecular signature of CSC resistant /sensitive of 243 pb with 179 genes of which 152 genes are up- regulated and 27 genes down-regulated in CSC resistant to Paclitaxel, so a genomic predictors for Tax-sensitivity in CSC resistant to Paclitaxel can be derived from BTCL and may be helpful for better understanding the mechanisms of resistance to Taxanes and the implication of CSC in this resistance in order to better select of cytotoxic treatment in breast cancer patients and identification of others potential markers for targeted therapies in the future .3- we tested the impact of the alteration of genomic and proteic parameters or the mutations of some genes like tau (MAPT),Tubulin K- ALPHA (TUB A1B) Tubulin alpha-6 (TUB A1C) Tubulin beta 3 (TUBB3) and Stathmin (STMN1), unfortunately we did'nt identify a mutations to be correlated to BTCL response to Taxanes .4- we try to study at the level of proteins by immunohistochemistry on the tissue micro- array and cyto-micro-array for some parameters which have been already proved (in vitro) to be correlated with response to Taxanes , ( this part is actually ongoing).

No description available.